People with hemophilia were formerly at very high risk of infection with hepatitis C virus (HCV). Approximately 20% of HCV-infected patients spontaneously clear the virus. To identify correlates of spontaneous clearance of HCV, we studied a cohort of HCVinfected hemophilic subjects without human immunodeficiency virus infection who had never been treated with interferon. Plasma HCV RNA was persistently undetectable in 192 (27.0%) of 712 HCV-seropositive subjects. In multivariate analyses, HCV clearance was more likely in subjects infected with HCV at younger age, especially with infection before age 2 (40.1%) compared to after age 15 years (14.9%, P trend <0.0001), and with relatively recent infection, especially after 1983 (42.8%) compared to before 1969 (18.2%, P trend <0.0001). HCV clearance was marginally reduced with African ancestry (19%) and greatly increased with chronic hepatitis B virus (HBV) infection (59.1%, P=0.0006). Resolved HBV infection, coagulopathy types and severity, types of clotting factor treatment, and gender were not associated with HCV clearance. In conclusion, hemophilic subjects co-infected with chronic HBV and those infected with HCV before age 2 or after 1983 were significantly more likely to spontaneously clear HCV viremia.
Introduction
The majority of patients infected with hepatitis C virus (HCV) fail to mount an effective immune response and develop persistent infection that may lead to chronic liver disease.
Epidemiological data from populations at risk of HCV exposure suggest that 14% to 40% of people infected with HCV spontaneously clear the virus and have no detectable HCV RNA in plasma. [1] [2] [3] [4] [5] [6] [7] Single exposure to HCV, younger age at infection, female gender, and certain major histocompatibility complex genes are likely to be associated with a higher spontaneous clearance rate. 2, [5] [6] [7] [8] African Americans and perhaps Asian Americans appear to be less likely than Hispanic or Caucasian Americans to clear the virus spontaneously. 7, [9] [10] [11] Co-infection with human immunodeficiency virus 1 (HIV-1) is associated with significantly lower spontaneous HCV clearance, while chronic infection with hepatitis B virus (HBV) is associated with significantly higher spontaneous HCV clearance. 10, 12 People with hemophilia receiving clotting factor replacement therapy were at very high risk of infection with HCV before the introduction of donor screening and virus inactivation in the mid-1980s. [13] [14] [15] Of HCV antibody-positive patients with hemophilia, spontaneous clearance of HCV RNA has been reported in about 25% of those without HIV-1 co-infection compared to 10% or less of those with HIV-1 co-infection. 6, [16] [17] The clinical and epidemiological determinants of HCV clearance in hemophilic patients are not well defined, although clearance may be more frequent among those infected at a younger age. 6 Clearance, when it occurs, is almost always within 1-2 years of primary For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From infection. 18 The purpose of the current study was to identify clinical correlates of spontaneous HCV clearance in a well-characterized cohort of people with hemophilia who were infected with HCV without HIV-1.
Methods
Study subjects. The second Multicenter Hemophilia Cohort Study (MHCS-II) was established to better identify, quantify, and develop markers for complications of HCV, as well as later complications of HIV-1 and its treatment. 19 All patients at the collaborating comprehensive hemophilia treatment centers were invited to participate in the MHCS-II if they had reached age 13 years, had a congenital coagulation disorder [hemophilia A or B (congenital factor VIII or IX deficiency), vonWillebrand's disease, or other, hereafter referred to as hemophilia] and if, since January 1, 1993, they had had a positive result on a locally performed, licensed assay for HCV antibodies (anti-HCV), HIV-1 antibodies, or HIV-1 RNA. Earlier HCV and HIV-1 results were not considered to avoid false-positive results with first generation assays. All 1449 HIV-uninfected subjects who enrolled in the MHCS-II from 2001 to 2004 were eligible for the current analysis. As described, 18 some small fraction of subjects had lost anti-HCV prior to MHCS-II enrollment, but this was not considered in the current analysis. Data on consumption of alcohol during the year before knowledge of being infected with HCV were collected by questionnaire. One drink was defined as 45ml (1.5 oz) of liquor, 120 ml (4 oz) of wine, or 360 ml (12 oz of beer) and was estimated to contain 12 g of alcohol. 19 Additional information is available at https://mhcs-ii.rti.org. Excluding those Types of plasma exposures. Before the early to mid-1980s, when heat inactivation of enveloped viruses in clotting factor concentrate became standard practice, people with hemophilia were treated with non-heat-treated clotting factor concentrate (NHT), that was derived from large pools of plasma (20,000 to 50,000 donors), and with cryoprecipitate that pooled a few to a maximum of 20 single-donor units or fresh frozen plasma (subsequently referred to as cryo/plasma). Based on the types and the order of the treatment received, each subject in the current study was classified as having one of the three types of exposure: (1) cryo/plasma only; (2) cryo/plasma before NHT factor concentrate; (3) NHT concentrate before or without cryo/plasma.
Imputation of age and year at HCV infection.
We assumed that concentrate used after 31 December 1990 was non-infectious, but concentrate used prior to 31 December 1990 resulted in infection with any single exposure. This date was well after use of NHT concentrate had ceased in the mid-1980s.
However, sporadic cases of HCV transmission attributed to heat-treated clotting factor concentrates occurred over the next few years, until development and implementation of For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From more stringent virucidal treatments and exclusion of anti-HCV positive donors. 15 Therefore, for subjects in group 3 above, we assumed that HCV infection occurred as a consequence of the first exposure. For subjects in groups 1 and 2 above, the precise dates of infection were unknown, but occurred in the interval between the first and last potentially infectious exposures. We assumed that, for 'similar' groups of subjects, defined below, the age-at-infection curve was proportional to the age-at-exposure curve.
On the basis of this assumption, we estimated the age-at-exposure distribution using statistical methods, and imputed each subject's most likely age-at-infection as the expected value of this distribution, conditional on exposure within the individual's window. The imputed dates of infection were calculated by adding the imputed ages to the corresponding dates of birth. Exposure probabilities by age were estimated from exposure window data using an EM algorithm and non-parametric locally-weighted scatter plot smoother (EMS algorithm). [20] [21] While defining groups of subjects who could be pooled for purposes of imputation, we noted that naive estimates of age-at-exposure defined using the mid-points of the exposure windows were strongly dependent on the severity of hemophilia and the year of birth (data not shown). Therefore, for each severity group and date of birth, we applied the EMS algorithm using all subjects with the same severity and with dates of birth occurring within 2.5 years.
For analysis, age at infection was divided into approximate quartiles. These were age less than 2, 2-5, 6-15, and 16-60 years. In contrast, year of infection was divided into approximate quintiles to reflect eras of therapeutic plasma products. Specifically, these copies/ml, maximum 16,286 copies/ml) due to well-to-well contamination during processing. To rectify this, the independent laboratory re-tested all specimens that were RT-PCR positive up to 100,000 copies/ml (5% of all screening-positive samples and 6- 
Results
Spontaneous HCV clearance by ancestry and gender. Among the 712 HIV-negative, interferon-untreated subjects who currently or previously were anti-HCV positive, 192 (27.0%) had cleared HCV infection as established by the inability to detect HCV RNA in plasma (Table 1) . Subjects of African ancestry had a marginally lower HCV clearance rate (19.1%) than did those of non-African ancestry (28.0%, P=0.08). As is typical for inherited coagulation deficiencies, only 41 of 712 (5.8%) subjects in the study were females. HCV clearance had occurred in 22.0% of the female subjects compared to 27.3% of the male subjects (P=0.46).
Spontaneous HCV clearance by type and severity of the coagulation deficiency. The
HCV clearance rate did not differ significantly between subjects with hemophilia A (28.5%), hemophilia B (26.0%), or other coagulation deficiencies (17.2%, P=0.15). By severity, the HCV clearance rate was 30.0% with severe bleeding diathesis, 25.2% with moderate bleeding diathesis, and 20.5% with mild bleeding diathesis (P=0.06).
Spontaneous HCV clearance by type of factor treatment. There was no significant difference in HCV clearance rate by type of clotting factor replacement therapy. The HCV clearance rate was 24.6% among subjects who received only cryoprecipitate or plasma. It was 27.5% among subjects who received cryoprecipitate or plasma prior to later receipt of NHT factor concentrates. And it was 30.2% among subjects who received NHT factor concentrates only or before cryoprecipitate or plasma (P=0.52).
Age at infection and spontaneous HCV clearance. Based on available data on age at first treatment and the types of treatment, age at HCV infection could be imputed for 620 of 712 subjects. The median age at HCV infection for subjects who spontaneously cleared HCV viremia was 3.0 years (IQR: 8.0 years), which was significantly younger than that for subjects with chronic HCV infection (median: 8.0 years, IQR: 16 years, P<0.0001).
By quartile, HCV clearance rate was 40.1% for those infected before age 2, 29.7% for those infected at ages 2-5, 26.1% for those infected at ages 6-15, and 14.9% for those infected after age 15 ( Table 2 ). Compared to subjects who were infected with HCV of the 712 subjects on alcohol use during the year before the subject learned that he or she had HCV antibodies. As shown in Table 2 , HCV clearance rates by tertile of alcohol consumption were 27.3%, 16.3%, and 18.8%, respectively, compared to 30.4% among those who denied alcohol consumption (P trend =0.004).
Multivariate analysis. Because many subjects lacked information on alcohol use and HBV infection status, the primary multivariate analysis was restricted to the 620 subjects with complete data on the other variables (Table 3) 
Discussion
The outcome of HCV infection is determined by the balance of the dynamic interaction between the virus and the host immune defense, with many environmental and other host factors modifying this interaction. 10, 12 In this study of HIV-uninfected hemophilic subjects enrolled in the MHCS-II cohort, we examined the association of spontaneous HCV clearance with several variables postulated to be important. Like others, we found that spontaneous HCV clearance was significantly more frequent among subjects of nonAfrican ancestry and those with chronic HBV infection. Our major new findings were that HCV clearance also was significantly more frequent among those infected at a very young age and those infected after 1983.
Most of our subjects had been infected with HCV during childhood, and there was a striking and highly significant gradient between the age at infection and the proportion that had cleared HCV. Overall, 27% of our subjects had cleared HCV. However, we observed that a much higher proportion, 40.1%, of those infected before age 2 years had cleared HCV compared to only 14.9% of those infected after age 15 years. This
For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From difference was not confounded by the other variables. The median age at infection was 3 years for subjects who cleared HCV infection compared to 8 years among those in whom viremia persisted.
Our findings corroborate those of Messick, et al, who showed that the rate of spontaneous HCV clearance among 49 HIV-negative, anti-HCV positive hemophilic patients was significantly higher with younger age at infection. 6 Similarly, Vogt and colleagues 23 found HCV clearance in 45% of 67 children infected by blood transfusion at a mean age of 2.8 years. Despite these data, clearance is not a simple function of age. Among volunteer blood donors, all of whom were adults, Busch et al recently found no association between HCV clearance and age. 11 At the other end of the spectrum, only two (11%) of 18 children infected through mini transfusions at birth spontaneously cleared HCV. 24 Perhaps the likelihood of HCV clearance is related to age-specific differences in immune response that modify the interaction between virus and host immune defense, leaving the neonate vulnerable to chronic infection while an older child may be primed for clearance. The size of the inoculum may also influence the clearance rate. Because clotting factor therapy is calibrated to body size, younger hemophilic subjects may have received a smaller inoculum of HCV that might have increased the success of an immune response and the likelihood of viral clearance. The complex relationship between age and clearance of HCV contrasts with the higher likelihood of clearance of HBV with older age at infection. 25 For
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We also observed that the likelihood of spontaneous HCV clearance increased with the calendar year in which the patient was infected. Only 18.2% of those infected before 1969 had cleared HCV, compared to 42.8% of those infected after 1983, a highly significant difference that was not confounded by age at infection or the other variables.
Change in the pathogenesis of HCV itself is unlikely. Rather, the association probably reflects a lower likelihood of HCV clearance following HCV re-infection. [26] [27] We speculate that the higher clearance in subjects first infected after 1983 might be due to less frequent re-exposure and repeated infection because of improvements in heat treatment and other procedures to inactivate viruses in factor concentrates that occurred during the 1980s. Alternatively, bias could account for the calendar association. Co-infection with other viruses, especially HIV-1 and HBV, has been shown to modify the natural history of HCV infection. 10, 12 To better understand other correlates of HCV clearance without the potential confounding effect of HIV-1 infection, we restricted our current study to HIV-uninfected hemophilia subjects. While resolved HBV infection was not associated with spontaneous HCV clearance, the relatively few subjects with chronic HBV infection were 3.6-fold more likely to clear HCV. Similar findings were reported previously among people with hemophilia and other populations. 9, [30] [31] [32] [33] [34] This could be due prevalence of chronic HBV infection in our cohort is nearly identical to that found 15 years earlier by Troisi, et al. 36 African ancestry was associated with lower spontaneous HCV clearance in other populations. 7, 10, 11 The current study, with only 84 subjects of African ancestry, was not ideal for assessing the impact of this characteristic. Nonetheless, we observed HCV clearance in only 19.0% of our subjects of African ancestry compared to 28.0% among other subjects, a difference that was statistically significant after adjustment for age at and calendar year of infection. We did not have sufficient statistical power to disentangle the role of ancestry from that of chronic HBV infection, nor did we have enough females to assess the role of gender.
Alcohol use was reported to be associated with lower spontaneous HCV clearance. 9 As HCV clearance usually occurs within 1-2 years after infection 6 and as changes in health or medication use may have prompted MHCS-II participants to change their drinking habits, we analyzed historical use of alcohol (drinking during the year before knowledge of the participant's HCV positivity) rather than recent alcohol use. In our univariate analysis, alcohol use had a highly statistically significant association with a lower rate of HCV clearance. However, alcohol consumption was no longer associated with HCV in a There are several potential limitations of our study. First, because age at HCV infection with hemophilia is seldom known precisely, we used information on types of and age at first exposure to infectious HCV through clotting factor replacement therapy to impute age at infection. Although we used statistical methods to maximize the probability of an accurate imputation, these historical data are inherently imprecise. Similarly, our data on use of alcohol were self-reported, allowing not only for inaccuracy but also the possibility for bias. To focus on spontaneous HCV clearance, we excluded subjects who had received interferon. The included and excluded subjects were very similar in all variables that we analyzed except for alcohol usage and African ancestry (data not presented).
Finally, the hemophilic population differs from others, particularly with respect to very young age at infection, multiple and possibly simultaneous infections, and inclusion of only survivors in the cohort. Thus, the results from this study may not generalize to nonhemophilic populations.
In conclusion, among people with hemophilia, the likelihood of spontaneous HCV clearance was increased more than 3-fold with each of three variables-chronic HBV coinfection, HCV infection at a very young age, and HCV infection since 1983. These findings illustrate the importance non-genetic determinants in spontaneous recovery from HCV infection. * Alcohol use before knowledge out of being infected with HCV. One drink was defined as 45ml (1.5 oz) of liquor, 120 ml (4 oz) of wine, or 360 ml (12 oz of beer) and was estimated to contain 12 g of alcohol. 
